CB-03-10 (Cortexolone 17α-valerate-21-propionate) is a highly potent oral androgen receptor (AR) and Glucocorticoid Receptors (GR) antagonist for the treatment of solid tumors. It has the potential for first- and second-line therapy in pancreatic and colon cancers. Regulatory Toxicology shows oral dosing is safe and well-tolerated.
Cosmo is partnering with ICON PLC, one of the world’s largest contract research organizations (CRO), which provides specialized and experienced services in phase I oncology clinical trials.
CB-03-10 one patent granted in the U.S.A., Europe, Australia, Mexico, Korea, and Hong Kong.
Phase I study in patients with advanced refractory solid tumors (Pancreas, Colon, Prostate) (NCT 03863145) has begun, as of July 2022 clinical sites in the U.S. have been activated and screening of patients has commenced.